Recent genetic advances, including genome-wide association studies and the discovery of modifier genes, have significantly improved the understanding of disease mechanisms and therapeutic implications in long QT syndromes.
Advances may enable precision LQTS management; leaves open prospective validation of therapeutic targets.
Long QT syndrome refers to a characteristic abnormality of the electrocardiogram and it is associated with a form of ventricular tachycardia known as torsade-de-pointes and sudden arrhythmic death. It can occur as part of a hereditary syndrome or can be acquired usually because of drug administration. Here we review recent genetic, molecular and cellular discoveries and outline how they have furthered our understanding of this disease. Specifically we focus on compound mutations, genome wide association studies of QT interval, modifier genes and the therapeutic implications of this recent work.
No takes yet. Share an insight, caveat, or question.
Harmer et al. (2016) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: